Advertisement
Advertisement
U.S. markets open in 7 hours 29 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cidara Therapeutics, Inc. (CDTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.4613+0.0169 (+3.80%)
At close: 04:00PM EDT
0.4799 +0.02 (+4.03%)
After hours: 07:57PM EDT
Advertisement
Full screen
Loading interactive chart...
  • Benzinga

    Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock

    U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch. Cidara confirmed that the application filing of lead antifungal drug rezafungin as a potential first-line treatment for candidemia and invasive candidiasis remains on track for mid-2022, which HC Wainwright takes to mean as late as August. HC Wainwright lowered the price target to $6 from $7.50, citing the challenging capi

  • Zacks

    Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates

    Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

    SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided an update on its corporate activities and product pipeline. “We continue to advance our pipeline of Cloudbreak DFC product candidates,” said Jeffrey Stein, Ph.D., president and chief exe

Advertisement
Advertisement